Kawasaki disease: Current aspects on aetiopathogenesis and therapeutic management

Autoimmunity Reviews

Volumn 10, Issue 9, 2011, Pages 544-547

  Alexoudi, Iliana ^a   Kanakis, Meletios ^a   Kapsimali, Violetta ^a   Vaiopoulos, George ^a  

^a UNIVERSITY OF ATHENS   (Greece)

Author keywords

Aetiopathogenesis; Kawasaki disease; Treatment; Vasculitis

Indexed keywords

ABCIXIMAB; ACETYLSALICYLIC ACID; CORTICOSTEROID; ENTEROTOXIN; ETANERCEPT; GELATINASE B; IMMUNOGLOBULIN; INFLIXIMAB; LOW MOLECULAR WEIGHT HEPARIN; METHYLPREDNISOLONE; PREDNISOLONE; ULINASTATIN; WARFARIN;

ACUTE DISEASE; ANGIOCARDIOGRAPHY; ANTICOAGULANT THERAPY; CD8+ T LYMPHOCYTE; CORONARY ARTERY; CORONARY ARTERY ANEURYSM; CORONARY ARTERY DILATATION; CORONARY ARTERY OBSTRUCTION; ECHOCARDIOGRAPHY; ELECTROCARDIOGRAPHY; EXERCISE TEST; FOLLOW UP; GENETIC PREDISPOSITION; HEART MUSCLE ISCHEMIA; HUMAN; IMMUNE RESPONSE; LOW DRUG DOSE; LYMPHOCYTIC INFILTRATION; MUCOCUTANEOUS LYMPH NODE SYNDROME; NONHUMAN; REVIEW; VIRUS INFECTION;

CORONARY ARTERY DISEASE; HUMANS; MUCOCUTANEOUS LYMPH NODE SYNDROME;

EID: 79957891345     PISSN: 15689972     EISSN: 18730183     Source Type: Journal    
DOI: 10.1016/j.autrev.2011.04.005     Document Type: Review

References (26)

1. Rowley A.H., Baker S.C., Shulman S.T., Garcia F.L., Guzman-Cottrill J.A., Chou P., et al. Detection of antigen in bronchial epithelium and macrophages in acute Kawasaki disease by use of synthetic antibody. J Infect Dis 2004 Aug 15, 190(4):856-865.
2. Burgner D., Harnden A. Kawasaki disease: what is the epidemiology telling us about the etiology?. Int J Infect Dis 2005 Jul, 9(4):185-194.
3. Newburger J.W., Takahashi M., Gerber M.A., Gewitz M.H., Tani L.Y., Burns J.C., et al. Committee on Rheumatic Fever, Endocarditis and Kawasaki Disease; Council on Cardiovascular Disease in the Young; American Heart Association; American Academy of Pediatrics. Diagnosis, treatment, and long-term management of Kawasaki disease: a statement for health professionals from the Committee on Rheumatic Fever, Endocarditis and Kawasaki Disease, Council on Cardiovascular Disease in the Young, American Heart Association. Circulation 2004, 110(17):2747-2771. Oct 26.
4. Matsubara K., Fukaya T., Miwa K., Shibayama N., Nigami H., Harigaya H., et al. Development of serum IgM antibodies against superantigens of Staphylococcus aureus and Streptococcus pyogenes in Kawasaki disease. Clin Exp Immunol 2006 Mar, 143(3):427-434.
5. Rowley A.H., Shulman S.T. New developments in the search for the etiologic agent of Kawasaki disease. Curr Opin Pediatr 2007 Feb, 19(1):71-74.
6. Brown T.J., Crawford S.E., Cornwall M.L., Garcia F., Shulman S.T., Rowley A.H. CD8 Tlymphocytes and macrophages infiltrate coronary artery aneurysms in acute Kawasaki disease. J Infect Dis 2001 Oct 1, 184(7):940-943.
7. Rowley A.H., Shulman S.T. Pathogenesis and management of Kawasaki disease. Expert Rev Anti Infect Ther 2010 Feb, 8(2):197-203.
8. Rowley A.H., Baker S.C., Orenstein J.M., Shulman S.T. Searching for the cause of Kawasaki disease-cytoplasmic inclusion bodies provide new insight. Nat Rev Microbiol 2008 May, 6(5):394-401.
9. Rowley A.H., Eckerley C.A., Jäck H.M., Shulman S.T., Baker S.C. IgA plasma cells in vascular tissue of patients with Kawasaki syndrome. J Immunol 1997 Dec15, 159(12):5946-5955.
10. Yeung R.S. Kawasaki disease: update on pathogenesis. Curr Opin Rheumatol 2010 Sep, 22(5):551-560.
11. Newburger J.W., Takahashi M., Gerber M.A., Gewitz M.H., Tani L.Y., Burns J.C., et al. Committee on Rheumatic Fever, Endocarditis,and Kawasaki Disease, Council on Cardiovascular Disease in the Young, American Heart Association. Diagnosis, treatment, and long-term management of Kawasaki disease: a statement for health professionals from the Committee on Rheumatic Fever, Endocarditis, and Kawasaki Disease, Council on Cardiovascular Disease in the Young, American Heart Association. Pediatrics 2004 Dec, 114(6):1708-1733.
12. Leung D.Y. Kawasaki syndrome: immunomodulatory benefit and potential toxin neutralization by intravenous immune globulin. Clin Exp Immunol 1996 May, 104(Suppl 1):49-54.
13. Galeotti C., Bayry J., Kone-Paut I., Kaveri S.V. Kawasaki disease: aetiopathogenesis and therapeutic utility of intravenous immunoglobulin. Autoimmun Rev 2010 Apr, 9(6):441-448.
14. Kuo H.C., Liang C.D., Wang C.L., Yu H.R., Hwang K.P., Yang K.D. Serum albumin levelpredicts initial intravenous immunoglobulin treatment failure in Kawasakidisease. Acta Paediatr 2010 Oct, 99(10):1578-1583.
15. Manlhiot C., Yeung R.S., Chahal N., McCrindle B.W. Intravenous immunoglobulin preparation type: association with outcomes for patients with acute Kawasaki disease. Pediatr Allergy Immunol 2010 May, 21(3):515-521.
16. Miura M., Kohno K., Ohki H., Yoshiba S., Sugaya A., Satoh M. Effects of methylprednisolone pulse on cytokine levels in Kawasaki disease patients unresponsive to intravenous immunoglobulin. Eur J Pediatr 2008 Oct, 167(10):1119-1123.
17. Kobayashi T., Inoue Y., Otani T., Morikawa A., Kobayashi T., Takeuchi K., et al. Risk stratification in the decision to include prednisolone with intravenous immunoglobulin in primary therapy of Kawasaki disease. Pediatr Infect Dis J 2009 Jun, 28(6):498-502.
18. Choueiter N.F., Olson A.K., Shen D.D., Portman M.A. Prospective open-label trial of etanercept as adjunctive therapy for kawasaki disease. J Pediatr 2010 Dec, 157(6):960-966. e1.
19. Shirley D.A., Stephens I. Primary treatment of incomplete Kawasaki disease with infliximab and methylprednisolone in a patient with a contraindication to intravenous immune globulin. Pediatr Infect Dis J 2010 Oct, 29(10):978-979.
20. Burns J.C., Best B.M., Mejias A., Mahony L., Fixler D.E., Jafri H.S., et al. Infliximab treatment of intravenous immunoglobulin-resistant Kawasaki disease. J Pediatr 2008 Dec, 153(6):833-838.
21. Hirono K., Kemmotsu Y., Wittkowski H., Foell D., Saito K., Ibuki K., et al. Infliximab reduces the cytokine-mediated inflammation but does not suppress cellular infiltration of the vessel wall in refractory Kawasaki disease. Pediatr Res 2009 Jun, 65(6):696-701.
22. Lau A.C., Duong T.T., Ito S., Wilson G.J., Yeung R.S. Inhibition of matrix metalloproteinase-9 activity improves coronary outcome in an animal model of Kawasaki disease. Clin Exp Immunol 2009 Aug, 157(2):300-309.
23. Sakata K., Hamaoka K., Ozawa S., Niboshi A., Yahata T., Fujii M., et al. Matrix metalloproteinase-9 in vascular lesions and endothelial regulation in Kawasaki disease. Circ J 2010 Aug, 74(8):1670-1675.
24. Paredes N., Mondal T., Brandão L.R., Chan A.K. Management of myocardial infarction in children with Kawasaki disease. Blood Coagul Fibrinolysis 2010 Oct, 21(7):620-631.
25. Manlhiot C., Brandão L.R., Somji Z., Chesney A.L., MacDonald C., Gurofsky R.C., et al. Long-term anticoagulation in Kawasaki disease: Initial use of low molecular weight heparin is a viable option for patients with severe coronary artery abnormalities. Pediatr Cardiol 2010 Aug, 31(6):834-842.
26. Williams R.V., Wilke V.M., Tani L.Y., Minich L.L. Does Abciximab enhance regression of coronary aneurysms resulting from Kawasaki disease?. Pediatrics 2002 Jan, 109(1):E4.